Dr. Nando Bansal brings over 30 years of experience in leading Compound Development Teams in the biotech and pharmaceutical industry. During his career Dr. Bansal led over 30 project teams for  molecules that include mAbs and novel biologics such as mimetibodies, bispecifics. duobodies and fynomabs- delivering 15 NMEs and FIH, 8 Phase 2 POC, 4 late development and LCM projects. 

He is highly experienced in setting development strategy, focusing on creating asset and portfolio value, managing risks and costs. He has also led major alliances with Merck, GSK, Sanofi, Abbvie and many medium and small biotech companies. He gained drug development, project leadership, and alliance/integration leadership experience during his tenure at Johnson & Johnson (13 years), Takeda (5 years) and Pfizer/Wyeth (13 years). 

Dr. Bansal has a Ph.D. from St. John’s University in Pharmaceutics and a MBA from City University, New York. He has also taken strategic leadership courses at Harvard Business School and Wharton School of Business at University of Pennsylvania.